The results of this study show that the distribution of LRP5 rs556442 differed significantly between patients with only CHD and those with both NAFLD and CHD, and that the LRP5 rs556442 GG genotype contributed to the risk of NAFLD in CHD patients. The gene discussed is LRP5; the disease is metabolic dysfunction-associated steatotic liver disease.